Dr. Shanel Bhagwandin opened the surgical oncology program at the Jupiter Medical Center in Southeast Florida. He brought with him the specialized resources needed to effectively treat peritoneal mesothelioma cancer.
Board Certified in Surgery
Hyperthermic Intraperitoneal Chemotherapy
Bhagwandin has expertise in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). This treatment combination has proven effective for several abdominal malignancies, including peritoneal mesothelioma.
Cytoreductive Surgery with HIPEC
Bhagwandin remains affiliated with the renowned Mount Sinai Hospital Icahn School of Medicine in New York, where he previously worked.
Having grown up in South Florida, he returned to the state in 2017. He arrived as the only board-certified complex general surgical oncologist in the four-county area surrounding Jupiter.
His arrival has expanded the entire gastrointestinal cancer program at the Jupiter Medical Center. He handles pancreatic, liver, stomach, colon, rectal and bile duct cancers. He also treats benign abdominal tumors, bile duct injuries and pancreatic cysts.
Bhagwandin will continue his role at Mount Sinai as Medical Director of Surgical Oncology Network Development. He is also an Assistant Professor of Surgical Oncology at the Icahn School of Medicine.
His continued affiliation with the Mount Sinai network allows for a variety of shared resources. Patients at the Jupiter Medical Center will have greater access to ground-breaking clinical trials.
Bhagwandin’s time in New York sharpened his interest in mesothelioma, a rare and aggressive cancer caused by exposure to asbestos. Mount Sinai is a highly regarded specialty center for both peritoneal and pleural mesothelioma.
Several of his patients in New York had come from the Jupiter area, all seeking a proven specialty center.
“It was a great opportunity for me to come back to Florida to serve the people here,” he said. “There are only a limited number of surgeons available to offer this kind of specialized treatment. Patients in this area will not have to travel so far anymore.”
The cytoreduction/HIPEC combination has played a major role in extending survival for peritoneal mesothelioma patients. However, it is not available at many cancer centers.
Cytoreduction is a complex, meticulous procedure that involves removing all visible tumor cells throughout the abdominal cavity. It may include removing parts of various organs, along with the entire lining around the abdomen.
Specialty centers combine it with HIPEC, which involves circulating a heated chemotherapy solution within the abdomen for up to 90 minutes before draining it.
HIPEC uses a drug mixture much stronger than conventional chemotherapy. It is designed to kill any hard-to-reach tumor cells left behind after the cytoreduction.
“When you tell a patient there is a chance he’ll come out of the operating room with no disease left inside, it’s something he’s never heard before,” Bhagwandin said. “That’s powerful. That motivates patients to fight this cancer.”
Bhagwandin graduated from the Lake Erie College of Osteopathic Medicine. He did a residency at the University of Illinois, along with a fellowship and an internship at Mount Sinai.
His professional memberships include the Society of Surgical Oncology, Americas Hepato-Pancreato-Biliary Association (AHPBA) and the American College of Surgery.
He speaks English and Spanish.
Disclaimer: Dr. Shanel Bhagwandin has no professional affiliation with Asbestos.com.
Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers. Read More